Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 113

1.

Management of patients with multidrug-resistant tuberculosis.

Lange C, Aarnoutse RE, Alffenaar JWC, Bothamley G, Brinkmann F, Costa J, Chesov D, van Crevel R, Dedicoat M, Dominguez J, Duarte R, Grobbel HP, Günther G, Guglielmetti L, Heyckendorf J, Kay AW, Kirakosyan O, Kirk O, Koczulla RA, Kudriashov GG, Kuksa L, van Leth F, Magis-Escurra C, Mandalakas AM, Molina-Moya B, Peloquin CA, Reimann M, Rumetshofer R, Schaaf HS, Schön T, Tiberi S, Valda J, Yablonskii PK, Dheda K.

Int J Tuberc Lung Dis. 2019 Jun 1;23(6):645-662. doi: 10.5588/ijtld.18.0622.

PMID:
31315696
2.

Implementation and effectiveness of evriMED with short messages service (SMS) reminders and tailored feedback compared to standard care on adherence to treatment among tuberculosis patients in Kilimanjaro, Tanzania: proposal for a cluster randomized controlled trial.

Sumari-de Boer M, Pima FM, Ngowi KM, Chelangwa GM, Mtesha BA, Minja LM, Semvua HH, Mpagama S, Mmbaga BT, Nieuwkerk PT, Aarnoutse RE.

Trials. 2019 Jul 12;20(1):426. doi: 10.1186/s13063-019-3483-4.

3.

Pharmacokinetics of pyrazinamide during the initial phase of tuberculous meningitis treatment.

Stemkens R, Litjens CHC, Dian S, Ganiem AR, Yunivita V, van Crevel R, Te Brake LHM, Ruslami R, Aarnoutse RE.

Int J Antimicrob Agents. 2019 Sep;54(3):371-374. doi: 10.1016/j.ijantimicag.2019.06.010. Epub 2019 Jun 14.

PMID:
31202922
4.

Failure with acquired resistance of an optimised bedaquiline-based treatment regimen for pulmonary Mycobacterium avium complex disease.

Zweijpfenning SMH, Schildkraut JA, Coolen JPM, Ruesen C, Koenraad E, Janssen A, Ruth MM, de Jong AS, Kuipers S, Aarnoutse RE, Magis-Escurra C, Hoefsloot W, van Ingen J.

Eur Respir J. 2019 Jul 11;54(1). pii: 1900118. doi: 10.1183/13993003.00118-2019. Print 2019 Jul. No abstract available.

PMID:
31000671
5.

Optimal Sampling Strategies for Therapeutic Drug Monitoring of First-Line Tuberculosis Drugs in Patients with Tuberculosis.

Saktiawati AMI, Harkema M, Setyawan A, Subronto YW, Sumardi, Stienstra Y, Aarnoutse RE, Magis-Escurra C, Kosterink JGW, van der Werf TS, Alffenaar JC, Sturkenboom MGG.

Clin Pharmacokinet. 2019 Apr 17. doi: 10.1007/s40262-019-00763-3. [Epub ahead of print]

PMID:
30997650
6.

Personalized Tuberculosis Treatment Through Model-Informed Dosing of Rifampicin.

van Beek SW, Ter Heine R, Keizer RJ, Magis-Escurra C, Aarnoutse RE, Svensson EM.

Clin Pharmacokinet. 2019 Jun;58(6):815-826. doi: 10.1007/s40262-018-00732-2.

PMID:
30671890
7.

A bedaquiline/clofazimine combination regimen might add activity to the treatment of clinically relevant non-tuberculous mycobacteria.

Ruth MM, Sangen JJN, Remmers K, Pennings LJ, Svensson E, Aarnoutse RE, Zweijpfenning SMH, Hoefsloot W, Kuipers S, Magis-Escurra C, Wertheim HFL, van Ingen J.

J Antimicrob Chemother. 2019 Apr 1;74(4):935-943. doi: 10.1093/jac/dky526.

PMID:
30649327
8.

Conflicting Findings on an Intermediate Dose of Rifampicin for Pulmonary Tuberculosis.

Te Brake LHM, Boeree MJ, Aarnoutse RE.

Am J Respir Crit Care Med. 2019 May 1;199(9):1166-1167. doi: 10.1164/rccm.201811-2101LE. No abstract available.

9.

Protein binding of rifampicin is not saturated when using high-dose rifampicin.

Litjens CHC, Aarnoutse RE, van Ewijk-Beneken Kolmer EWJ, Svensson EM, Colbers A, Burger DM, Boeree MJ, Te Brake LHM; PanACEA-MAMS-TB-01 Team .

J Antimicrob Chemother. 2019 Apr 1;74(4):986-990. doi: 10.1093/jac/dky527.

PMID:
30597025
10.

Rifampicin Alters Metformin Plasma Exposure but Not Blood Glucose Levels in Diabetic Tuberculosis Patients.

Te Brake LHM, Yunivita V, Livia R, Soetedjo N, van Ewijk-Beneken Kolmer E, Koenderink JB, Burger DM, Santoso P, van Crevel R, Alisjahbana B, Aarnoutse RE, Ruslami R; on behalf of the TANDEM Consortium.

Clin Pharmacol Ther. 2019 Mar;105(3):730-737. doi: 10.1002/cpt.1232. Epub 2018 Oct 29.

11.

The stability of antimycobacterial drugs in media used for drug susceptibility testing.

Schoutrop ELM, Brouwer MAE, Jenniskens JCA, Ferro BE, Mouton JW, Aarnoutse RE, van Ingen J.

Diagn Microbiol Infect Dis. 2018 Dec;92(4):305-308. doi: 10.1016/j.diagmicrobio.2018.06.015. Epub 2018 Jun 27.

PMID:
30025972
12.

Assessment of the Additional Value of Verapamil to a Moxifloxacin and Linezolid Combination Regimen in a Murine Tuberculosis Model.

Pieterman ED, Te Brake LHM, de Knegt GJ, van der Meijden A, Alffenaar JC, Bax HI, Aarnoutse RE, de Steenwinkel JEM.

Antimicrob Agents Chemother. 2018 Aug 27;62(9). pii: e01354-18. doi: 10.1128/AAC.01354-18. Print 2018 Sep.

13.

Evaluation of dried blood spot sampling for pharmacokinetic research and therapeutic drug monitoring of anti-tuberculosis drugs in children.

Martial LC, Kerkhoff J, Martinez N, Rodríguez M, Coronel R, Molinas G, Roman M, Gomez R, Aguirre S, Jongedijk E, Huisman J, Touw DJ, Pérez D, Chaparro G, Gonzalez F, Aarnoutse RE, Alffenaar JW, Magis-Escurra C.

Int J Antimicrob Agents. 2018 Jul;52(1):109-113. doi: 10.1016/j.ijantimicag.2018.04.020. Epub 2018 May 8.

PMID:
29751121
14.

Manual punch versus automated flow-through sample desorption for dried blood spot LC-MS/MS analysis of voriconazole.

Martial LC, van den Hombergh E, Tump C, Halmingh O, Burger DM, van Maarseveen EM, Brüggemann RJ, Aarnoutse RE.

J Chromatogr B Analyt Technol Biomed Life Sci. 2018 Jul 1;1089:16-23. doi: 10.1016/j.jchromb.2018.04.039. Epub 2018 Apr 27.

PMID:
29747155
15.

Greater Early Bactericidal Activity at Higher Rifampicin Doses Revealed by Modeling and Clinical Trial Simulations.

Svensson RJ, Svensson EM, Aarnoutse RE, Diacon AH, Dawson R, Gillespie SH, Moodley M, Boeree MJ, Simonsson USH.

J Infect Dis. 2018 Aug 14;218(6):991-999. doi: 10.1093/infdis/jiy242.

PMID:
29718390
16.

Determination of protein-unbound, active rifampicin in serum by ultrafiltration and Ultra Performance Liquid Chromatography with UV detection. A method suitable for standard and high doses of rifampicin.

van Ewijk-Beneken Kolmer EWJ, Teulen MJA, van den Hombergh ECA, van Erp NE, Te Brake LHM, Aarnoutse RE.

J Chromatogr B Analyt Technol Biomed Life Sci. 2017 Sep 15;1063:42-49. doi: 10.1016/j.jchromb.2017.08.004. Epub 2017 Aug 4.

17.

Pharmacokinetics, Tolerability, and Bacteriological Response of Rifampin Administered at 600, 900, and 1,200 Milligrams Daily in Patients with Pulmonary Tuberculosis.

Aarnoutse RE, Kibiki GS, Reither K, Semvua HH, Haraka F, Mtabho CM, Mpagama SG, van den Boogaard J, Sumari-de Boer IM, Magis-Escurra C, Wattenberg M, Logger JGM, Te Brake LHM, Hoelscher M, Gillespie SH, Colbers A, Phillips PPJ, Plemper van Balen G, Boeree MJ; PanACEA Consortium.

Antimicrob Agents Chemother. 2017 Oct 24;61(11). pii: e01054-17. doi: 10.1128/AAC.01054-17. Print 2017 Nov.

18.

The Role of Efflux Pumps in Tuberculosis Treatment and Their Promise as a Target in Drug Development: Unraveling the Black Box.

Te Brake LHM, de Knegt GJ, de Steenwinkel JE, van Dam TJP, Burger DM, Russel FGM, van Crevel R, Koenderink JB, Aarnoutse RE.

Annu Rev Pharmacol Toxicol. 2018 Jan 6;58:271-291. doi: 10.1146/annurev-pharmtox-010617-052438. Epub 2017 Jul 17. Review.

PMID:
28715978
19.

Dried Blood Spot Sampling for Tacrolimus and Mycophenolic Acid in Children: Analytical and Clinical Validation.

Martial LC, Hoogtanders KEJ, Schreuder MF, Cornelissen EA, van der Heijden J, Joore MA, Van Maarseveen EM, Burger DM, Croes S, Brüggemann RJM, Aarnoutse RE.

Ther Drug Monit. 2017 Aug;39(4):412-421. doi: 10.1097/FTD.0000000000000422.

PMID:
28700522
20.

A Population Pharmacokinetic Model Incorporating Saturable Pharmacokinetics and Autoinduction for High Rifampicin Doses.

Svensson RJ, Aarnoutse RE, Diacon AH, Dawson R, Gillespie SH, Boeree MJ, Simonsson USH.

Clin Pharmacol Ther. 2018 Apr;103(4):674-683. doi: 10.1002/cpt.778. Epub 2017 Aug 7.

21.

Metformin and daclatasvir: absence of a pharmacokinetic-pharmacodynamic drug interaction in healthy volunteers.

Smolders EJ, Colbers A, de Kanter CTMM, Velthoven-Graafland K, Wolberink LT, van Ewijk-Beneken Kolmer N, Drenth JPH, Aarnoutse RE, Tack CJ, Burger DM.

Br J Clin Pharmacol. 2017 Oct;83(10):2225-2234. doi: 10.1111/bcp.13323. Epub 2017 Jun 6.

22.

Activity of moxifloxacin and linezolid against Mycobacterium tuberculosis in combination with potentiator drugs verapamil, timcodar, colistin and SQ109.

de Knegt GJ, van der Meijden A, de Vogel CP, Aarnoutse RE, de Steenwinkel JE.

Int J Antimicrob Agents. 2017 Mar;49(3):302-307. doi: 10.1016/j.ijantimicag.2016.11.027. Epub 2017 Feb 2.

PMID:
28162983
23.

Dried Blood Spot sampling in psychiatry: Perspectives for improving therapeutic drug monitoring.

Martial LC, Aarnoutse RE, Mulder M, Schellekens A, Brüggemann RJM, Burger DM, Schene AH, Batalla A.

Eur Neuropsychopharmacol. 2017 Mar;27(3):205-216. doi: 10.1016/j.euroneuro.2017.01.009. Epub 2017 Jan 24. Review.

PMID:
28130001
24.

Cost Evaluation of Dried Blood Spot Home Sampling as Compared to Conventional Sampling for Therapeutic Drug Monitoring in Children.

Martial LC, Aarnoutse RE, Schreuder MF, Henriet SS, Brüggemann RJ, Joore MA.

PLoS One. 2016 Dec 12;11(12):e0167433. doi: 10.1371/journal.pone.0167433. eCollection 2016.

25.

A preliminary study searching for the right dose of tacrolimus in very young (≤4 years) renal transplant patients.

Martial LC, Verstegen RH, Cornelissen EA, Aarnoutse RE, Schreuder MF, Brüggemann RJ.

J Pharm Pharmacol. 2016 Nov;68(11):1366-1372. doi: 10.1111/jphp.12639. Epub 2016 Sep 27.

PMID:
27669677
26.

Moxifloxacin Is a Potent In Vitro Inhibitor of OCT- and MATE-Mediated Transport of Metformin and Ethambutol.

Te Brake LH, van den Heuvel JJ, Buaben AO, van Crevel R, Bilos A, Russel FG, Aarnoutse RE, Koenderink JB.

Antimicrob Agents Chemother. 2016 Nov 21;60(12):7105-7114. Print 2016 Dec.

27.

Measuring Plasma Concentrations of Ribavirin: First Report From a Quality Control Program.

Smolders EJ, Kan R, de Kanter CT, van Luin M, Aarnoutse RE, Touw DJ, Burger DM.

Ther Drug Monit. 2016 Oct;38(5):646-7. doi: 10.1097/FTD.0000000000000319. No abstract available.

PMID:
27355493
28.

Does Weight Impact Anidulafungin Pharmacokinetics?

Lempers VJ, van Rongen A, van Dongen EP, van Ramshorst B, Burger DM, Aarnoutse RE, Knibbe CA, Brüggemann RJ.

Clin Pharmacokinet. 2016 Oct;55(10):1289-1294. doi: 10.1007/s40262-016-0401-8.

29.

A new trial design to accelerate tuberculosis drug development: the Phase IIC Selection Trial with Extended Post-treatment follow-up (STEP).

Phillips PP, Dooley KE, Gillespie SH, Heinrich N, Stout JE, Nahid P, Diacon AH, Aarnoutse RE, Kibiki GS, Boeree MJ, Hoelscher M.

BMC Med. 2016 Mar 23;14:51. doi: 10.1186/s12916-016-0597-3.

30.

Inhibitory Potential of Antifungal Drugs on ATP-Binding Cassette Transporters P-Glycoprotein, MRP1 to MRP5, BCRP, and BSEP.

Lempers VJ, van den Heuvel JJ, Russel FG, Aarnoutse RE, Burger DM, Brüggemann RJ, Koenderink JB.

Antimicrob Agents Chemother. 2016 May 23;60(6):3372-9. doi: 10.1128/AAC.02931-15. Print 2016 Jun.

31.

Pharmacokinetics and target attainment of mycophenolate in pediatric renal transplant patients.

Martial LC, Jacobs BA, Cornelissen EA, de Haan AF, Koch BC, Burger DM, Aarnoutse RE, Schreuder MF, Brüggemann RJ.

Pediatr Transplant. 2016 Jun;20(4):492-9. doi: 10.1111/petr.12695. Epub 2016 Feb 29.

PMID:
26923724
32.

Inhibitory potential of tuberculosis drugs on ATP-binding cassette drug transporters.

Te Brake LH, Russel FG, van den Heuvel JJ, de Knegt GJ, de Steenwinkel JE, Burger DM, Aarnoutse RE, Koenderink JB.

Tuberculosis (Edinb). 2016 Jan;96:150-7. doi: 10.1016/j.tube.2015.08.004. Epub 2015 Oct 9.

PMID:
26682943
33.

Dose Reduction of Caspofungin in Intensive Care Unit Patients with Child Pugh B Will Result in Suboptimal Exposure.

Martial LC, Brüggemann RJ, Schouten JA, van Leeuwen HJ, van Zanten AR, de Lange DW, Muilwijk EW, Verweij PE, Burger DM, Aarnoutse RE, Pickkers P, Dorlo TP.

Clin Pharmacokinet. 2016 Jun;55(6):723-33. doi: 10.1007/s40262-015-0347-2.

34.

Feasibility of Real Time Medication Monitoring Among HIV Infected and TB Patients in a Resource-Limited Setting.

de Sumari-de Boer IM, van den Boogaard J, Ngowi KM, Semvua HH, Kiwango KW, Aarnoutse RE, Nieuwkerk PT, Kibiki GS.

AIDS Behav. 2016 May;20(5):1097-107. doi: 10.1007/s10461-015-1254-0.

PMID:
26604004
35.

A Step toward an Optimized Rifampin Dose Completed.

Boeree MJ, Diacon AH, Dawson R, Narunsky K, du Bois J, Venter A, Phillips PP, Gillespie SH, McHugh TD, Hoelscher M, Heinrich N, Rehal S, van Soolingen D, van Ingen J, Magis-Escurra C, Burger D, Plemper van Balen G, Aarnoutse RE.

Am J Respir Crit Care Med. 2015 Aug 15;192(4):525-6. doi: 10.1164/rccm.201506-1061LE. No abstract available.

PMID:
26278799
36.

Drug-interactions of azole antifungals with selected immunosuppressants in transplant patients: strategies for optimal management in clinical practice.

Lempers VJ, Martial LC, Schreuder MF, Blijlevens NM, Burger DM, Aarnoutse RE, Brüggemann RJ.

Curr Opin Pharmacol. 2015 Oct;24:38-44. doi: 10.1016/j.coph.2015.07.002. Epub 2015 Jul 25. Review.

PMID:
26218924
37.

Pharmacokinetic Modeling and Optimal Sampling Strategies for Therapeutic Drug Monitoring of Rifampin in Patients with Tuberculosis.

Sturkenboom MG, Mulder LW, de Jager A, van Altena R, Aarnoutse RE, de Lange WC, Proost JH, Kosterink JG, van der Werf TS, Alffenaar JW.

Antimicrob Agents Chemother. 2015 Aug;59(8):4907-13. doi: 10.1128/AAC.00756-15. Epub 2015 Jun 8.

38.

Fundament and Prerequisites for the Application of an Antifungal TDM Service.

Brüggemann RJ, Aarnoutse RE.

Curr Fungal Infect Rep. 2015;9(2):122-129. Review.

39.

Limited sampling strategy for prolonged-release tacrolimus in renal transplant patients by use of the dried blood spot technique.

van Boekel GA, Donders AR, Hoogtanders KE, Havenith TR, Hilbrands LB, Aarnoutse RE.

Eur J Clin Pharmacol. 2015 Jul;71(7):811-6. doi: 10.1007/s00228-015-1863-6. Epub 2015 May 17.

40.

Impact of special patient populations on the pharmacokinetics of echinocandins.

Muilwijk EW, Lempers VJ, Burger DM, Warris A, Pickkers P, Aarnoutse RE, Brüggemann RJ.

Expert Rev Anti Infect Ther. 2015 Jun;13(6):799-815. doi: 10.1586/14787210.2015.1028366. Epub 2015 May 6. Review.

PMID:
25947367
41.

An interlaboratory quality control programme for the measurement of tuberculosis drugs.

Aarnoutse RE, Sturkenboom MG, Robijns K, Harteveld AR, Greijdanus B, Uges DR, Touw DJ, Alffenaar JW.

Eur Respir J. 2015 Jul;46(1):268-71. doi: 10.1183/09031936.00177014. Epub 2015 Apr 16. No abstract available.

42.

Exposure to total and protein-unbound rifampin is not affected by malnutrition in Indonesian tuberculosis patients.

te Brake LH, Ruslami R, Later-Nijland H, Mooren F, Teulen M, Apriani L, Koenderink JB, Russel FG, Burger DM, Alisjahbana B, Wieringa F, van Crevel R, Aarnoutse RE.

Antimicrob Agents Chemother. 2015;59(6):3233-9. doi: 10.1128/AAC.03485-14. Epub 2015 Mar 23.

43.

A dose-ranging trial to optimize the dose of rifampin in the treatment of tuberculosis.

Boeree MJ, Diacon AH, Dawson R, Narunsky K, du Bois J, Venter A, Phillips PP, Gillespie SH, McHugh TD, Hoelscher M, Heinrich N, Rehal S, van Soolingen D, van Ingen J, Magis-Escurra C, Burger D, Plemper van Balen G, Aarnoutse RE; PanACEA Consortium.

Am J Respir Crit Care Med. 2015 May 1;191(9):1058-65. doi: 10.1164/rccm.201407-1264OC.

PMID:
25654354
44.

Early phase evaluation of SQ109 alone and in combination with rifampicin in pulmonary TB patients.

Heinrich N, Dawson R, du Bois J, Narunsky K, Horwith G, Phipps AJ, Nacy CA, Aarnoutse RE, Boeree MJ, Gillespie SH, Venter A, Henne S, Rachow A, Phillips PP, Hoelscher M, Diacon AH; Pan African Consortium for the Evaluation of Antituberculosis Antibiotics (PanACEA); Pan African Consortium for the Evaluation of Antituberculosis Antibiotics PanACEA.

J Antimicrob Chemother. 2015 May;70(5):1558-66. doi: 10.1093/jac/dku553. Epub 2015 Jan 27.

PMID:
25630641
45.

Determination of the HCV Protease Inhibitor Telaprevir in Plasma and Dried Blood Spot by Liquid Chromatography-Tandem Mass Spectrometry.

Verweij-van Wissen CP, de Graaff-Teulen MJ, de Kanter CT, Aarnoutse RE, Burger DM.

Ther Drug Monit. 2015 Oct;37(5):626-33. doi: 10.1097/FTD.0000000000000189.

PMID:
25627404
46.

Acquired drug resistance: we can do more than we think!

Alffenaar JW, Gumbo T, Aarnoutse RE.

Clin Infect Dis. 2015 Mar 15;60(6):969-70. doi: 10.1093/cid/ciu1146. Epub 2014 Dec 19. No abstract available.

PMID:
25527653
47.

Delayed trough level measurement with the use of prolonged-release tacrolimus.

van Boekel GA, Aarnoutse RE, Hoogtanders KE, Havenith TR, Hilbrands LB.

Transpl Int. 2015 Mar;28(3):314-8. doi: 10.1111/tri.12499. Epub 2014 Dec 17.

48.

Five year results of an international proficiency testing programme for measurement of antifungal drug concentrations.

Lempers VJ, Alffenaar JW, Touw DJ, Burger DM, Uges DR, Aarnoutse RE, Brüggemann RJ.

J Antimicrob Chemother. 2014 Nov;69(11):2988-94. doi: 10.1093/jac/dku242. Epub 2014 Jul 7.

PMID:
25006236
49.

[Therapeutic drug monitoring of antimicrobials].

Mouton JW, Aarnoutse RE.

Ned Tijdschr Geneeskd. 2014;158:A7520. Review. Dutch.

PMID:
24988163
50.

Population pharmacokinetics and limited sampling strategy for first-line tuberculosis drugs and moxifloxacin.

Magis-Escurra C, Later-Nijland HM, Alffenaar JW, Broeders J, Burger DM, van Crevel R, Boeree MJ, Donders AR, van Altena R, van der Werf TS, Aarnoutse RE.

Int J Antimicrob Agents. 2014 Sep;44(3):229-34. doi: 10.1016/j.ijantimicag.2014.04.019. Epub 2014 Jun 9.

PMID:
24985091

Supplemental Content

Loading ...
Support Center